Salix Pharmaceuticals, Ltd.  

(Public, NASDAQ:SLXP)   Watch this stock  
Find more results for Oceana Inc.�
110.74
+0.79 (0.72%)
Real-time:   12:26PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 106.23 - 111.25
52 week 49.36 - 120.00
Open 110.84
Vol / Avg. 359,903.00/1.12M
Mkt cap 6.97B
P/E 51.28
Div/yield     -
EPS 2.16
Shares 62.94M
Beta 1.20
Inst. own 104%
Jun 13, 2014
Salix Pharmaceuticals Inc Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
May 8, 2014
Q1 2014 Salix Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 11, 2014
Salix Pharmaceuticals Inc at ROTH Conference
Feb 27, 2014
Q4 2013 Salix Pharmaceuticals Inc Earnings Conference Call - Webcast
Feb 27, 2014
Q4 2013 Salix Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 20.29% 15.32%
Operating margin 37.26% 29.10%
EBITD margin - 32.95%
Return on average assets 8.36% 5.94%
Return on average equity 29.54% 21.98%
Employees 525 -
CDP Score - -

Address

8510 Colonnade Center Drive
RALEIGH, NC 27615
United States - Map
+1-919-8621000 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Officers and directors

Thomas W. D'Alonzo Independent Chairman of the Board
Bio & Compensation  - Reuters
Carolyn J. Logan President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Adam C. Derbyshire Chief Financial Officer, Executive Vice President - Finance and Administration
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
William P. Forbes Executive Vice President - Research and Development, Chief Medical Officer, Chief Development Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rick D. Scruggs Executive Vice President - Business Development
Age: 53
Bio & Compensation  - Reuters
John F. Chappell Independent Director
Age: 76
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
William P. Keane Independent Director
Age: 58
Bio & Compensation  - Reuters
Mark A. Sirgo Pharm.D. Independent Director
Age: 59
Bio & Compensation  - Reuters